Score the coincidence
Boltzmann Ensemble covalent ligandability combines pocket fit, cysteine reactivity and sulfur exposure within each conformer, then weights the joint score across the modeled ensemble. This preserves a distinction that separate averages lose: favorable properties occurring together versus appearing in different structures. A calibration procedure evaluates the resulting covalent-ligandability readout within the tested setup.
From a promising state to a capturable site
A useful extension is to pair the ensemble score with molecular fit and access, then reaction-barrier or kinetic analysis. The question becomes whether the ligand can enter a relevant state and react before that opportunity disappears. BioTwin has these component methods; a fully calibrated, experimentally tested composition remains to be established.
Where the evidence holds
Computational calibration studies support site prioritization on small, selected panels. The conformers and Boltzmann weights are model-derived rather than measured equilibrium populations. A target-specific comparison should include a static baseline, matched reactive and unreactive controls, and sensitivity to sampling and weights. Chemical proteomics supplies complementary evidence of engagement in the biological context.
Different approaches answer different parts of the covalent-site question.
| Question | Familiar approach | BioTwin | Why it matters |
|---|---|---|---|
| Structural opportunity | A single-structure assessment evaluates the supplied geometry; ensemble docking can examine multiple structures. | Scores fit, reactivity and exposure together in each conformer before aggregation. | Distinguishes joint opportunity from favorable properties that occur in different conformations. |
| Biological context | DrugMap measures cysteine ligandability experimentally across cancer cell contexts. | Models structural opportunities and their sensitivity to the chosen ensemble. | The model can nominate hypotheses; contextual engagement data can challenge them. |
| Candidate progression | A site score helps nominate a residue for follow-up. | Can be investigated alongside access geometry and capture kinetics. | A site becomes a specific entry-and-reaction hypothesis, with each added step requiring evidence. |
This is a comparison of scientific roles. No head-to-head advantage over DrugMap or contemporary ensemble-docking methods is claimed.